银屑病是一种慢性、炎症性、多系统疾病，全球人口大约有2-3%受其影响。该疾病的发生是由遗传和环境因素触发的，这些因素同时激活树突状细胞和角质细胞，促使产生肿瘤坏死因子α、白细胞介素17、白细胞介素23、白细胞介素22和白细胞介素1β等前炎症细胞因子。对银屑病的病理生理学有深入的了解，显著推动了安全高效的新型治疗方法的发展，目前已批准四类生物治疗药物用于治疗中至重度银屑病，分别为肿瘤坏死因子α抑制剂、白细胞介素23抑制剂、抗白细胞介素12/23和抗白细胞介素17制剂，此外还有小分子抑制剂如阿普雷米拉斯等。银屑病与共病疾病有关，包括银屑病性关节炎、心血管疾病、代谢综合征、精神障碍、恶性肿瘤以及炎症性肠病。对于同时患有银屑病和炎症性肠病的患者，强烈建议避免使用白细胞介素17抑制剂，因为它们可能加重胃肠道疾病。我们的目标是对接受白细胞介素17抑制剂治疗的银屑病患者发展炎症性肠病病变的文献进行全面综述，同时结合病例报告以强调对这些患者的密切随访的必要性。

Psoriasis is a chronic, inflammatory, multisystemic disease which affects approximately 2-3% of the population globally, whose onset is triggered by genetic and environmental factors which activate both dendritic cells and keratinocytes, resulting in the production of proinflammatory cytokines such as tumor necrosis factor alpha, interleukin 17, interleukin 23, interleukin 22, and interleukin 1β. An in-depth understanding of the pathophysiology of psoriasis led to significant advances in the development of safe and efficient novel therapeutic options, with four classes of biologic therapy being approved for the management of moderate to severe psoriasis: tumor necrosis factor alpha inhibitors, interleukin 23 inhibitors, anti-interleukin 12/23 agents, anti-interleukin 17 agents, as well as small-molecule inhibitors, such as apremilast. Psoriasis is associated with comorbid conditions, namely psoriatic arthritis, cardiovascular disease, metabolic syndrome, psychiatric disorders, malignancy, as well as inflammatory bowel disease. For patients affected by both psoriasis and inflammatory bowel disease, there is a strong recommendation to avoid IL-17 inhibitors since they may play a part in the exacerbation of the gastrointestinal disease. Our aim was to perform a thorough literature review regarding the development of inflammatory bowel disease lesions in psoriasis patients treated with IL-17 inhibitors, along with a case presentation to emphasize the need for close follow-up of these patients.